Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 351–400 of 840 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT02365883	Transrectal Photoacoustic Imaging of the Prostate	—	terminated	Feb 19, 2015	Stanford University	PI passed away	Other (stated, no rule matched)
NCT03152448	Prospective Prolaris Value and Efficacy(P-PROVE)	—	terminated	May 15, 2017	Myriad Genetic Laboratories, Inc.	Myriad has sufficient data to do an analysis on the primary objective, durability, and has made the…	Other (stated, no rule matched)
NCT03823001	Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of…	N/A	withdrawn	Jan 30, 2019	Case Comprehensive Cancer Center	low accrual	Enrollment / accrual
NCT03367819	Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced…	Phase 1 / Phase 2	terminated	Dec 11, 2017	Sanofi	The study was stopped after interim analysis indicated that overall result was not sufficient to…	Efficacy / futility
NCT04331717	Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC)	Phase 2	withdrawn	Apr 2, 2020	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	accrual on hold	Enrollment / accrual
NCT02913131	Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor…	Phase 1 / Phase 2	terminated	Sep 23, 2016	Rahul Aggarwal	Low Accrual	Enrollment / accrual
NCT02945813	SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate…	Phase 2	terminated	Oct 26, 2016	Swiss Cancer Institute	Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened to…	Enrollment / accrual
NCT04765423	Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease	N/A	withdrawn	Feb 21, 2021	Case Comprehensive Cancer Center	Poor patient accrual	Enrollment / accrual
NCT02349386	Maintaining Suppression of Testosterone With Transdermal Estradiol Gel(MASTERS)	Phase 2	terminated	Jan 28, 2015	BHR Pharma, LLC	Inability to recruit patients	Enrollment / accrual
NCT04357717	ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting	—	terminated	Apr 22, 2020	Exosome Diagnostics, Inc.	project reprioritization	Other (stated, no rule matched)
NCT04221828	Trial of NanoPac Focal Therapy for Prostate Cancer	Phase 2	terminated	Jan 9, 2020	NanOlogy, LLC	Lack of enrollment	Enrollment / accrual
NCT03366792	Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted…	N/A	terminated	Dec 8, 2017	NYU Langone Health	Investigators chose to discontinue the study based on interim findings	Other (stated, no rule matched)
NCT02362451	Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0…	Phase 2	terminated	Feb 13, 2015	National Cancer Institute (NCI)	Slow accrual.	Enrollment / accrual
NCT04960956	Glycosylation of Exosomes in Prostate and Urothelial Carcinoma	—	terminated	Jul 14, 2021	Indiana University	Could not identify a replacement Principal Investigator.	Investigator
NCT04393831	A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy	N/A	terminated	May 19, 2020	Weill Medical College of Cornell University	This study was terminated to facilitate accrual under NCT05155501	Enrollment / accrual
NCT01650285	Cabazitaxel and Radiation For Patients With Prostate Cancer	Phase 2	terminated	Jul 26, 2012	Brown University	slow recruitment and lost funding	Enrollment / accrual
NCT01650350	Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal…	Phase 2	terminated	Jul 26, 2012	Brown University	Study stopped 10/24/13 secondary to lack of patients/slow enrollment	Enrollment / accrual
NCT00482157	Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance	N/A	withdrawn	Jun 4, 2007	Stanford University	not stated	Not stated
NCT03441464	Feasibility of the LUM Imaging System for Detection of Prostate Cancer	Phase 1 / Phase 2	terminated	Feb 22, 2018	Lumicell, Inc.	Interim analysis indicated a change in study design to collect in vivo data	Efficacy / futility
NCT01826838	Study of Dasatinib, Androgen Deprivation Therapy and Radiation(BrUOGPR255)	Phase 1	withdrawn	Apr 9, 2013	Brown University	Lack of patients	Other (stated, no rule matched)
NCT03630393	Ultralow Versus Standard Pneumoperitoneum Pressure(Ultralow)	N/A	terminated	Aug 14, 2018	OhioHealth	PI left institution	Investigator
NCT00594620	Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy	Phase 2	terminated	Jan 15, 2008	University of Kansas Medical Center	Terminated due to poor accrual and without sufficient patients or data to report on any outcomes.	Enrollment / accrual
NCT02628535	Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1	terminated	Dec 11, 2015	MacroGenics	Business decision (not for safety reasons)	Safety / toxicity
NCT03689582	Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer	Phase 2	terminated	Sep 28, 2018	University of Michigan Rogel Cancer Center	due to pandemic related constraints	COVID-19 / pandemic
NCT04339920	Spermine Measuring Device Evaluation Protocol	—	withdrawn	Apr 9, 2020	Chinese University of Hong Kong	No funding	Funding
NCT01098331	Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer	N/A	terminated	Apr 2, 2010	University of Southampton	Closed early due to poor recruitment	Enrollment / accrual
NCT03800784	Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer	Phase 2 / Phase 3	withdrawn	Jan 11, 2019	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Lack of funding	Funding
NCT02648919	Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer	Phase 2	terminated	Jan 7, 2016	University of Hawaii	low accrual	Enrollment / accrual
NCT02767921	sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or…	Phase 1	terminated	May 11, 2016	University of Southern California	Insufficient accrual	Enrollment / accrual
NCT03712930	Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous…	Phase 2	terminated	Oct 19, 2018	BeiGene	Sponsor's decision to revisit the development approach for prostate cancer.	Sponsor / business decision
NCT03495479	Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance(CAMPAS)	—	withdrawn	Apr 12, 2018	Omnitura Therapeutics, Inc.	No funding	Funding
NCT03886493	Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer	Phase 2	terminated	Mar 22, 2019	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Low accrual due to COVID-19 pandemic.	COVID-19 / pandemic
NCT04052204	Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced…	Phase 1 / Phase 2	terminated	Aug 9, 2019	Pfizer	Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not…	Other (stated, no rule matched)
NCT02565901	Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic…	Phase 1 / Phase 2	terminated	Oct 1, 2015	University of Washington	Terminated due to insufficient funding	Funding
NCT00354432	Soy Protein/Effexor Hormone Therapy for Prostate Cancer	Phase 3	terminated	Jul 20, 2006	Wake Forest University Health Sciences	Stopped by the DSMB for lack of effect per interim stopping rule.	Other (stated, no rule matched)
NCT00161252	Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer…	—	withdrawn	Sep 12, 2005	University of Medicine and Dentistry of New Jersey	not stated	Not stated
NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And…(AtezoVax)	Phase 2	withdrawn	Jul 15, 2019	University of Utah	funding source withdrawn	Funding
NCT02963051	A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic,…	Phase 1	terminated	Nov 15, 2016	Daniel George, MD	Study stopped due to lack of efficacy.	Efficacy / futility
NCT04403568	Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular…	Early Phase 1	withdrawn	May 27, 2020	The University of Texas Health Science Center at San Antonio	No subjects were enrolled in this study, the PI will seek funding and revise the protocol for…	Enrollment / accrual
NCT03545165	177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC	Phase 1 / Phase 2	terminated	Jun 4, 2018	Weill Medical College of Cornell University	Sponsor withdrawal	Other (stated, no rule matched)
NCT04296578	Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant…	Phase 1	withdrawn	Mar 5, 2020	Stanford University	Study did not start	Other (stated, no rule matched)
NCT02985021	Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies	Phase 2	terminated	Dec 7, 2016	Seattle Institute for Biomedical and Clinical Research	Competing studies	Other (stated, no rule matched)
NCT03829930	Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer	Phase 1	terminated	Feb 4, 2019	George Washington University	Sponsor discontinued the drug	Other (stated, no rule matched)
NCT02108613	Living Well on Androgen Deprivation Therapy	N/A	withdrawn	Apr 9, 2014	British Columbia Cancer Agency	It was deemed not enough funding and the initial funding returned and study withdrawn (never opened…	Enrollment / accrual
NCT00911079	Pilot Study of a Catheter-based Ultrasound Hyperthermia System	N/A	terminated	Jun 1, 2009	University of California, San Francisco	Low Accrual	Enrollment / accrual
NCT02432820	Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate…	—	terminated	May 4, 2015	Stanford University	Business decision	Sponsor / business decision
NCT04486846	Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)	N/A	withdrawn	Jul 27, 2020	Duke University	Principal Investigator left Duke University	Investigator
NCT03927924	High-intensity Focused Ultrasound Study	N/A	terminated	Apr 25, 2019	Chinese University of Hong Kong	due to funding	Funding
NCT03532308	Nutrition and Prostate Cancer	Phase 3	terminated	May 22, 2018	Yale University	Unable to meet recruitment goals.	Enrollment / accrual
NCT01802307	Focal Therapy for Prostate Cancer	Phase 2	withdrawn	Mar 1, 2013	University of Maryland, Baltimore	Study was withdrawn	Other (stated, no rule matched)

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Jun 14, 2022source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules